HMOX1 and fatty liver disease: In contrast, liver sections from mice treated with the HO-1 inhibitor ZnPP showed aggravated hepatic steatosis, inflammation, and fibrosis (Figure 1(a)) and further elevated serum transaminase levels (Figure 1(b)).